A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

NCT06548230 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndrome(MDS)
Acute Myelogenous Leukemia (AML)

Interventions

DRUG: Nadunolimab
DRUG: Azacitidine
DRUG: Venetoclax

Sponsor

M.D. Anderson Cancer Center